Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma Journal Article


Authors: Cheung, N. K. V.; Heller, G.
Article Title: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma
Abstract: We examined the efficacy of five commonly used drugs, teniposide (VM26), cisplatin (CDDP), cyclophosphamide (CPM), doxorubicin (DOXO), and vincristine (VCR) in a retrospective analysis of 44 clinical trials of induction chemotherapy for stage IV neuroblastoma patients newly diagnosed at older than 1 year of age. Dose intensity (DI) of each drug was calculated as milligrams per square meter per week. Linear regression analyses showed that the Dis of VM26 and CDDP had the greatest influence on clinical outcomes (ie, proportion of major response, median survival, and median progression-free survival [PFS]), while those of CPM and DOXO were less significant. VCR had no influence on the three clinical end points. Although many protocols extended treatment to more than 1 year, none of these end points correlated positively with the duration of therapy. Twenty-one weeks appeared adequate for achieving superior response, median survival, and median PFS. These results suggest that maximal dose intensification of selective drugs over a short duration may improve the outcome of patients with poor-risk neuroblastoma. © 1991 by American Society of Clinical Oncology.
Keywords: survival; adolescent; child; controlled study; survival rate; retrospective studies; major clinical study; review; cisplatin; doxorubicin; neoplasm staging; metastasis; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; neuroblastoma; multivariate analysis; drug dose; teniposide; intravenous drug administration; human; male; female; priority journal
Journal Title: Journal of Clinical Oncology
Volume: 9
Issue: 6
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1991-06-01
Start Page: 1050
End Page: 1058
Language: English
DOI: 10.1200/jco.1991.9.6.1050
PUBMED: 2033419
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 September 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Glenn Heller
    399 Heller
  2. Nai-Kong Cheung
    648 Cheung